

Biogen Idec Inc.: PharmaVitae Profile

<https://marketpublishers.com/r/BC037D0D8B2EN.html>

Date: October 2010

Pages: 118

Price: US\$ 5,700.00 (Single User License)

ID: BC037D0D8B2EN

Abstracts

Introduction

This analysis examines the historical and forecast performance for Biogen Idec in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

Gain insight into Biogen Idec's strategic outlook across the next 6 years

Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for Biogen Idec over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

Benchmark Biogen Idec's performance against key rivals in the prescription pharmaceutical sector

See how the launch of company's multiple sclerosis portfolio is in transition as

oral treatments become available

Contents

Executive Summary

Key findings

Prescription pharmaceutical sales and growth rate performance, 2003–15

Financial performance, 2003–15

Biogen Idec: PharmaVitae forecasts at a glance

Strategic insight

Biogen Idec's key multiple sclerosis franchise in transition

Biogen MS franchise, with a high dependency on new launches, will remain central to the company's future performance, as sales growth of Rituxan slows

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

About

ABOUT THIS PROFILE

PharmaVitae Explorer database

Chapter structure

Quarterly news update

Company introduction

Company sales

Company financials

Key products and competitors

Data sourcing

Analyst consensus

QUARTERLY NEWS UPDATE

Latest quarterly sales

Latest comment

Q1 2010

Q4 2009

Q3 2009

Q2 2009

Q1 2009

Latest prescription pharma product news

Q2 2010

Q1 2010

Q4 2009

Q3 2009

Q2 2009

Q1 2009

Latest corporate news

Q1 2010

Q4 2009

Q3 2009

Q2 2009

Q1 2009

Future product milestones

COMPANY INTRODUCTION

Biogen Idec Inc.: PharmaVitae Profile

Key findings

Background

M&A history

Conforma Therapeutics

Fumapharm AG

Syntonix

Biogen Idec loses out to Abbott for Facet

Current corporate structure

Biopharmaceuticals

COMPANY SALES

Key findings

Prescription pharmaceutical sales and growth rate analysis, 2003–15

Product analysis

Product analysis, 2003–09

Product analysis, 2009–15

Therapy area analysis

Geographic analysis

Launch/core/expiry analysis

Explanation of launch/core/expiry analysis

Launch analysis, 2009–15

Core analysis, 2009–15

Expiry analysis, 2009–15

Launch/core/expiry configuration, 2009–15

Molecule type analysis

Externalization analysis

COMPANY FINANCIALS

Key findings

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09

Operating costs and profit analysis

Operating costs and profit analysis, 2003–09

Operating cost ratio and profit margin analysis, 2003–09

Operating cost ratio and profit margin analysis, 2009–15

Operating costs and profit analysis, 2009–15

KEY PRODUCTS AND COMPETITORS

Key findings

Overview

Central nervous system

Avonex

Tysabri

Panaclar

Oncology

Rituxan royalties

APPENDIX

References

Abbreviations

About Datamonitor

I would like to order

Product name: Biogen Idec Inc.: PharmaVitae Profile

Product link: <https://marketpublishers.com/r/BC037D0D8B2EN.html>

Price: US\$ 5,700.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BC037D0D8B2EN.html>